What is the current AQP4 Antibody market size?

The AQP4 Antibody market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the AQP4 Antibody market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the AQP4 Antibody market?

Increasing demand for diagnostic tests and rising awareness of autoimmune diseases drive the market.

What are the major challenges facing the AQP4 Antibody market?

High development costs and stringent regulatory requirements pose significant challenges.

Which regions are leading the AQP4 Antibody market?

North America and Europe are the leading regions due to advanced healthcare infrastructure.

Who are the top companies in the AQP4 Antibody market?

Leading companies include bioMerieux, Euroimmun, and Oxford Biomedica.

What are the future opportunities in the AQP4 Antibody market?

Emerging economies and increasing research activities present future outlook opportunities.

How does technology impact the AQP4 Antibody market?

Advances in diagnostic technologies improve test accuracy and efficiency.

What is the current regulatory landscape of the AQP4 Antibody market?

Regulatory bodies such as FDA and EMA oversee the market with strict guidelines.

What is the future outlook of the AQP4 Antibody market?

The market is expected to grow significantly due to increasing demand for diagnostic tests.

AQP4 Antibody Growth Trends & Strategic Outlook 2033

AQP4 Antibody by Application (Western Blot (WB), Immunochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC), Others), by Types (Monoclonal, Polyclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

AQP4 Antibody Market Overview

The AQP4 Antibody market refers to the global industry involved in the research, development, and distribution of antibodies targeting the Aquaporin-4 protein, which plays a crucial role in various neurological disorders. As the AQP4 Antibody market size continues to expand, driven by increasing demand for innovative treatments, the growth outlook and market forecast indicate a promising future for industry players. The market forecast suggests a significant increase in the AQP4 Antibody market, with the global market size estimated to be around $1.4 billion in 2025, and the industry expansion is expected to be driven by advancements in technology, changing regulations, and shifting consumer behavior.

Loading chart…

The AQP4 Antibody market is expected to grow at a CAGR of around 10% during the forecast period, driven by macro drivers such as increasing prevalence of neurological disorders, advancements in technology, and rising demand for innovative treatments. Key forces shaping the industry include technology shifts, regulations, and competitive intensity. The largest region in the AQP4 Antibody market is North America, while the fastest-growing region is expected to be Asia-Pacific. As the market continues to evolve, industry players must stay ahead of the curve by investing in research and development, expanding their product portfolios, and strengthening their distribution networks to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Atlas Antibodies; Boster Bio; Absolute Antibody; VWR; Alomone Labs; Synaptic Systems; St John's Laboratory; Abcam; Cell Signaling Technology; ABclonal; Nordic BioSite; Merck; LifeSpan BioSciences; Bioss; Novus Biologicals; RayBiotech; Abnova Corporation; Beijing Solarbio; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The AQP4 Antibody market is poised for significant growth, driven by increasing demand for innovative treatments and rising awareness about neuromyelitis optica spectrum disorder (NMOSD).

Growth Drivers2 items

The growing prevalence of NMOSD and the expanding AQP4 Antibody market size are expected to drive the market forward, with a growth forecast that indicates a substantial increase in the coming years.

Advances in technology, such as the development of more sensitive and specific diagnostic tests, are also fueling the growth of the AQP4 Antibody market by enabling earlier and more accurate diagnoses.

Restraints2 items

High development costs and stringent regulatory requirements are major restraints in the AQP4 Antibody market, potentially limiting the entry of new players and hindering the launch of new treatments.

The lack of awareness about NMOSD among patients and healthcare professionals in certain regions may also impede the growth of the AQP4 Antibody market size by reducing demand for diagnostic tests and treatments.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies presents opportunities for the development of novel AQP4 Antibody treatments, which could significantly enhance the growth forecast of the market.

Expanding into emerging markets, where there is a growing need for innovative treatments for NMOSD, can also provide a significant boost to the AQP4 Antibody market by increasing its global reach and penetration.

Challenges2 items

Competition from established pharmaceutical companies and the need to demonstrate the efficacy and safety of new treatments are significant challenges in the AQP4 Antibody market, requiring substantial investment in research and development.

Pricing pressures and reimbursement issues may also impact the profitability of AQP4 Antibody treatments, affecting the overall growth forecast and AQP4 Antibody market size in the coming years.

Market Segmentation

Loading chart…

The Application segment of the AQP4 Antibody market refers to the various uses of AQP4 antibodies in research, diagnostics, and therapeutics. This segment contributes significantly to the overall AQP4 Antibody market size, as it encompasses a wide range of applications, including neuromyelitis optica spectrum disorder (NMOSD) diagnosis and research. Understanding the AQP4 Antibody segmentation is crucial for market players to identify opportunities and trends in the industry.

The Types segment of the AQP4 Antibody market includes subtypes such as monoclonal and polyclonal antibodies. Monoclonal antibodies are produced by a single clone of cells and recognize a specific epitope, while polyclonal antibodies are produced by multiple clones of cells and recognize multiple epitopes. This segmentation category is essential for understanding the market taxonomy and identifying areas of growth and development in the AQP4 Antibody market.

AQP4 Antibody Segmentation Breakdown9 items

Application

Western Blot (WB)

Immunochemistry (IHC)

Immunoprecipitation (IP)

Immunocytochemistry (ICC)

Others

Types

Monoclonal

Polyclonal

Regional Insights

Loading chart…

The AQP4 Antibody market growth is poised to witness significant regional variations, with North America emerging as the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of advanced diagnostic techniques and rising investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high policies awareness, and significant demographics-related demand. In Europe, factors such as favorable policies, robust infrastructure, and a strong pharmaceutical industry are expected to drive growth. Asia Pacific's growth will be fueled by increasing adoption of innovative treatments, expanding healthcare infrastructure, and growing demographics. Latin America and Middle East & Africa will witness moderate growth, driven by improving infrastructure and rising healthcare investments.

The regional forecast suggests that the AQP4 Antibody market will experience significant growth, with each region presenting unique opportunities and challenges. Understanding these regional dynamics is crucial for stakeholders to navigate the AQP4 Antibody market growth and capitalize on emerging trends.

Competitive Landscape

The AQP4 Antibody market structure is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The AQP4 Antibody competitive landscape is driven by the need for high-quality products, with companies focusing on differentiation through technology, service model, and channel strength. Global players have a strong presence, but local companies are also gaining traction through regional expansion and partnerships.

Companies in the AQP4 Antibody market are adopting various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To differentiate themselves, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are implementing these strategies:

Atlas Antibodies: regional expansion

Boster Bio: innovation pipeline

Absolute Antibody: premium pricing

VWR: OEM tie-ups

Alomone Labs: local manufacturing

Synaptic Systems: vertical integration

Key AQP4 Antibody Companies19 items

Atlas Antibodies

Boster Bio

Absolute Antibody

VWR

Alomone Labs

Synaptic Systems

St John's Laboratory

Abcam

Cell Signaling Technology

ABclonal

Nordic BioSite

Merck

LifeSpan BioSciences

Bioss

Novus Biologicals

RayBiotech

Abnova Corporation

Beijing Solarbio

Jingjie PTM BioLab

Market Ecosystem

The AQP4 Antibody ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. This complex network creates and captures value through the development, manufacturing, and distribution of AQP4 Antibody products. Understanding the AQP4 Antibody ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — providing essential components

OEMs / manufacturers — producing AQP4 Antibody products

Technology providers — developing innovative testing methods

Distributors / channel partners — facilitating product delivery

Service providers / after-sales — offering support and maintenance

End users / buyers — utilizing AQP4 Antibody products in research and diagnostics

Regulators/standards bodies — establishing guidelines and approvals

In the AQP4 Antibody ecosystem, control points are primarily influenced by regulators and standards bodies, as they dictate the approval and adoption of products. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact product development and distribution. Switching costs and partnerships also play a significant role, as companies may need to adapt to new technologies or form alliances to remain competitive. Furthermore, interoperability requirements can affect the compatibility of AQP4 Antibody products with existing systems, highlighting the need for a thorough understanding of the ecosystem's complexities.

Recent Industry Insights

The AQP4 Antibody industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships have been forged to enhance research and development capabilities, while mergers and acquisitions have led to consolidation and expansion of product portfolios. Notably, several companies have launched innovative products and technologies, further advancing the industry. Regulatory changes have also played a crucial role in shaping the market, with updated guidelines and approvals influencing the growth trajectory. Moreover, a shift in consumer and enterprise trends has been observed, driven by increasing demand for effective treatments and rising awareness about the importance of AQP4 antibodies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the AQP4 Antibody market. The market attractiveness of AQP4 Antibody is substantial, driven by the growing prevalence of neuromyelitis optica spectrum disorder (NMOSD) and the increasing demand for targeted therapies. The competitive intensity is moderate, with a few key players dominating the landscape. The long-term outlook for the AQP4 Antibody market is promising, with a growing focus on innovation and research and development. The AQP4 Antibody market outlook is expected to be shaped by advancements in innovation landscape, with a focus on improving treatment options and patient outcomes. However, the demand-supply balance may be affected by key risk factors, including regulatory challenges and reimbursement issues.

11 items

1. Executive Summary

2. AQP4 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global AQP4 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global AQP4 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Western Blot (WB)

6.1.2. Immunochemistry (IHC)

6.1.3. Immunoprecipitation (IP)

6.1.4. Immunocytochemistry (ICC)

6.1.5. Others

6.2. Global AQP4 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal

6.2.2. Polyclonal

6.3. Global AQP4 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global AQP4 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global AQP4 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global AQP4 Antibody Market Competition by Key Manufacturers

8.1. Global AQP4 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global AQP4 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Atlas Antibodies

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Boster Bio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Absolute Antibody

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. VWR

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alomone Labs

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Synaptic Systems

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. St John's Laboratory

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abcam

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cell Signaling Technology

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. ABclonal

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Nordic BioSite

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Merck

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. LifeSpan BioSciences

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Bioss

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Novus Biologicals

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. RayBiotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Abnova Corporation

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Beijing Solarbio

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Jingjie PTM BioLab

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global AQP4 Antibody Market

Figure 4: Global AQP4 Antibody Market: Drivers

Figure 5: Global AQP4 Antibody Market: Challenges

Figure 6: Global AQP4 Antibody Market: Trends

Figure 7: Global AQP4 Antibody Market: Opportunity

Figure 8: Global AQP4 Antibody Market: Restraint

Figure 9: Global AQP4 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global AQP4 Antibody Market Value (USD Million) By Region

Figure 15: Global AQP4 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global AQP4 Antibody Market Value (USD Million) By Region

Figure 23: Global AQP4 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

91 items

Table 1: Market Segmentation Analysis

Table 2: Global AQP4 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global AQP4 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global AQP4 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global AQP4 Antibody Market Value (USD Million) By Region

Table 10: Global AQP4 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global AQP4 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global AQP4 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global AQP4 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Atlas Antibodies Basic Information And Sales Area

Table 31: Atlas Antibodies. Products Portfolio

Table 32: Boster Bio Basic Information And Sales Area

Table 33: Boster Bio. Products Portfolio

Table 34: Absolute Antibody Basic Information And Sales Area

Table 35: Absolute Antibody. Products Portfolio

Table 36: VWR Basic Information And Sales Area

Table 37: VWR. Products Portfolio

Table 38: Alomone Labs Basic Information And Sales Area

Table 39: Alomone Labs. Products Portfolio

Table 40: Synaptic Systems Basic Information And Sales Area

Table 41: Synaptic Systems. Products Portfolio

Table 42: St John's Laboratory Basic Information And Sales Area

Table 43: St John's Laboratory. Products Portfolio

Table 44: Abcam Basic Information And Sales Area

Table 45: Abcam. Products Portfolio

Table 46: Cell Signaling Technology Basic Information And Sales Area

Table 47: Cell Signaling Technology. Products Portfolio

Table 48: ABclonal Basic Information And Sales Area

Table 49: ABclonal. Products Portfolio

Table 50: Nordic BioSite Basic Information And Sales Area

Table 51: Nordic BioSite. Products Portfolio

Table 52: Merck Basic Information And Sales Area

Table 53: Merck. Products Portfolio

Table 54: LifeSpan BioSciences Basic Information And Sales Area

Table 55: LifeSpan BioSciences. Products Portfolio

Table 56: Bioss Basic Information And Sales Area

Table 57: Bioss. Products Portfolio

Table 58: Novus Biologicals Basic Information And Sales Area

Table 59: Novus Biologicals. Products Portfolio

Table 60: RayBiotech Basic Information And Sales Area

Table 61: RayBiotech. Products Portfolio

Table 62: Abnova Corporation Basic Information And Sales Area

Table 63: Abnova Corporation. Products Portfolio

Table 64: Beijing Solarbio Basic Information And Sales Area

Table 65: Beijing Solarbio. Products Portfolio

Table 66: Jingjie PTM BioLab Basic Information And Sales Area

Table 67: Jingjie PTM BioLab. Products Portfolio

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Market Value (USD Million) (2025-2032) By Types

Table 71: Global Market Share (%) By Types (2032)

Table 72: Global AQP4 Antibody Market Value (USD Million) By Region

Table 73: Global AQP4 Antibody Market Share (%) By Region (2025-2032)

Table 74: North America Market Value (USD Million) (2025-2032) By Country

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: North America Market Value (USD Million) (2025-2032) By Types

Table 77: Europe Market Value (USD Million) (2025-2032) By Country

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Types

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 83: South America Market Value (USD Million) (2025-2032) By Country

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Types

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 89: Research Programs/Design For This Report

Table 90: Key Data Information From Secondary Sources

Table 91: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

AQP4 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Atlas Antibodies; Boster Bio; Absolute Antibody; VWR; Alomone Labs; Synaptic Systems; St John's Laboratory; Abcam; Cell Signaling Technology; ABclonal; Nordic BioSite; Merck; LifeSpan BioSciences; Bioss; Novus Biologicals; RayBiotech; Abnova Corporation; Beijing Solarbio; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The AQP4 Antibody market is poised for significant growth, driven by increasing demand for innovative treatments and rising awareness about neuromyelitis optica spectrum disorder (NMOSD).

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

AQP4 Antibody Segmentation Breakdown9 items

Application

Western Blot (WB)

Immunochemistry (IHC)

Immunoprecipitation (IP)

Immunocytochemistry (ICC)

Others

Types

Monoclonal

Polyclonal

Regional Insights

Loading chart…

Competitive Landscape

Atlas Antibodies: regional expansion

Boster Bio: innovation pipeline

Absolute Antibody: premium pricing

VWR: OEM tie-ups

Alomone Labs: local manufacturing

Synaptic Systems: vertical integration

Key AQP4 Antibody Companies19 items

Atlas Antibodies

Boster Bio

Absolute Antibody

VWR

Alomone Labs

Synaptic Systems

St John's Laboratory

Abcam

Cell Signaling Technology

ABclonal

Nordic BioSite

Merck

LifeSpan BioSciences

Bioss

Novus Biologicals

RayBiotech

Abnova Corporation

Beijing Solarbio

Jingjie PTM BioLab

Market Ecosystem

Raw material suppliers — providing essential components

OEMs / manufacturers — producing AQP4 Antibody products

Technology providers — developing innovative testing methods

Distributors / channel partners — facilitating product delivery

Service providers / after-sales — offering support and maintenance

End users / buyers — utilizing AQP4 Antibody products in research and diagnostics

Regulators/standards bodies — establishing guidelines and approvals

Recent Industry Insights

Analyst Overview

Table of Contents